COMPASS Pathways stock falls 6.97 percent after TD Cowen summit

COMPASS Pathways stock (ISIN US20451W1018) stood at USD 13.75 in after-hours trading on Nasdaq on September 23, 2026, down 6.97 percent from the previous close of USD 14.78. The move followed a TD Cowen summit that highlighted both launch preparation for COMP360 and regulatory dependencies.

Launch plans meet regulatory steps

As Investing.com reported on September 23, 2026, management discussed FDA review, federal DEA rescheduling and state-level authorization as separate steps before a broad launch. The company also described commercial preparation covering more than 8,000 interventional psychiatry centers.

The summit discussion linked COMP360 to treatment-resistant depression and a rolling New Drug Application process. That makes the regulatory sequence central to the investment case, because clinical progress alone does not establish a commercial launch date.

COMP005 data add clinical depth

Yahoo Finance reported on September 9, 2026, that the Phase 3 COMP005 trial enrolled 258 original U.S. participants. At week 52, the original 25 mg COMP360 group showed an average 13-point reduction from baseline on the MADRS scale, while the original placebo group recorded a 10-point reduction after receiving COMP360.

Across Part C participants receiving a 25 mg dose, response rates were 40 to 45 percent and remission rates were approximately 30 percent during the period after treatment. These figures give the stock a measurable clinical reference point as the company moves from trial data toward regulatory execution.

Stock remains below yearly high

The September 23, 2026 price of USD 13.75 was 13.36 percent below the 52-week high of USD 15.87 and 181.76 percent above the 52-week low of USD 4.88. Market capitalization stood at USD 1,855,195,306 on the same quote snapshot.

More news and analyses on COMPASS Pathways stock